Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh Acquires 250 Shares

Share on StockTwits

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh bought 250 shares of the company’s stock in a transaction on Monday, July 29th. The shares were acquired at an average cost of $106.01 per share, for a total transaction of $26,502.50. Following the completion of the acquisition, the director now directly owns 61,953 shares of the company’s stock, valued at approximately $6,567,637.53. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jason Aryeh also recently made the following trade(s):

  • On Monday, August 5th, Jason Aryeh purchased 746 shares of Ligand Pharmaceuticals stock. The shares were purchased at an average price of $90.01 per share, with a total value of $67,147.46.
  • On Wednesday, July 31st, Jason Aryeh purchased 4,004 shares of Ligand Pharmaceuticals stock. The shares were purchased at an average price of $99.22 per share, with a total value of $397,276.88.
  • On Tuesday, June 11th, Jason Aryeh purchased 250 shares of Ligand Pharmaceuticals stock. The shares were purchased at an average price of $107.01 per share, with a total value of $26,752.50.
  • On Wednesday, May 29th, Jason Aryeh bought 250 shares of Ligand Pharmaceuticals stock. The stock was bought at an average price of $111.01 per share, with a total value of $27,752.50.
  • On Friday, May 31st, Jason Aryeh bought 1,000 shares of Ligand Pharmaceuticals stock. The stock was bought at an average price of $109.51 per share, with a total value of $109,510.00.
  • On Monday, May 20th, Jason Aryeh bought 250 shares of Ligand Pharmaceuticals stock. The stock was bought at an average price of $112.01 per share, with a total value of $28,002.50.
  • On Tuesday, May 14th, Jason Aryeh bought 250 shares of Ligand Pharmaceuticals stock. The stock was bought at an average price of $112.51 per share, with a total value of $28,127.50.

NASDAQ:LGND opened at $91.77 on Friday. Ligand Pharmaceuticals Inc. has a twelve month low of $88.23 and a twelve month high of $278.62. The company has a current ratio of 13.23, a quick ratio of 13.15 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $106.99 and a 200-day moving average of $115.77. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 14.61, a price-to-earnings-growth ratio of 1.99 and a beta of 1.30.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.30. Ligand Pharmaceuticals had a net margin of 389.58% and a return on equity of 11.24%. The company had revenue of $24.99 million during the quarter, compared to analyst estimates of $21.01 million. During the same quarter last year, the firm posted $2.59 EPS. The business’s revenue for the quarter was down 72.2% on a year-over-year basis. On average, research analysts forecast that Ligand Pharmaceuticals Inc. will post 2.28 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Manchester Capital Management LLC purchased a new stake in Ligand Pharmaceuticals during the first quarter valued at about $26,000. Tower Research Capital LLC TRC lifted its stake in Ligand Pharmaceuticals by 188.6% during the second quarter. Tower Research Capital LLC TRC now owns 228 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 149 shares in the last quarter. FTB Advisors Inc. purchased a new stake in Ligand Pharmaceuticals during the second quarter valued at about $26,000. FinTrust Capital Advisors LLC lifted its stake in Ligand Pharmaceuticals by 64.4% during the first quarter. FinTrust Capital Advisors LLC now owns 337 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 132 shares in the last quarter. Finally, Valeo Financial Advisors LLC purchased a new stake in Ligand Pharmaceuticals during the second quarter valued at about $46,000.

A number of equities analysts recently issued reports on LGND shares. ValuEngine lowered shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “strong sell” rating and set a $95.00 target price for the company. in a research report on Thursday, August 8th. Argus set a $140.00 target price on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 10th. HC Wainwright reiterated a “buy” rating and issued a $214.00 target price (down previously from $254.00) on shares of Ligand Pharmaceuticals in a research report on Friday, May 3rd. Finally, BidaskClub upgraded shares of Ligand Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $165.83.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

See Also: Market Capitalization – What it Means for Investors

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.